Denosumab (Prolia), which is a monoclonal antibody targeting RANKL, has been approved since 2010 for the treatment of severe osteoporosis (38), showing efficacy in terms of reducing fractures and increasing bone mineral density (39, 40). This evidence concerns the gene TNFSF11 and osteoporosis.